- Home
- SAIA vs IONS Comparison
SAIA vs IONS Comparison
Compare SAIA & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIA
- IONS
- Stock Information
- Founded
- SAIA 1924
- IONS 1989
- Country
- SAIA United States
- IONS United States
- Employees
- SAIA N/A
- IONS N/A
- Industry
- SAIA Trucking Freight/Courier Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SAIA Industrials
- IONS Health Care
- Exchange
- SAIA Nasdaq
- IONS Nasdaq
- Market Cap
- SAIA 7.6B
- IONS 6.8B
- IPO Year
- SAIA 2002
- IONS 1991
- Fundamental
- Price
- SAIA $289.92
- IONS $42.00
- Analyst Decision
- SAIA Buy
- IONS Buy
- Analyst Count
- SAIA 18
- IONS 16
- Target Price
- SAIA $375.94
- IONS $58.25
- AVG Volume (30 Days)
- SAIA 624.2K
- IONS 2.0M
- Earning Date
- SAIA 07-25-2025
- IONS 07-31-2025
- Dividend Yield
- SAIA N/A
- IONS N/A
- EPS Growth
- SAIA N/A
- IONS N/A
- EPS
- SAIA 11.99
- IONS N/A
- Revenue
- SAIA $3,241,874,000.00
- IONS $717,253,000.00
- Revenue This Year
- SAIA $2.52
- IONS $9.08
- Revenue Next Year
- SAIA $7.17
- IONS $14.72
- P/E Ratio
- SAIA $24.34
- IONS N/A
- Revenue Growth
- SAIA 8.95
- IONS N/A
- 52 Week Low
- SAIA $229.12
- IONS $23.95
- 52 Week High
- SAIA $624.55
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- SAIA 54.23
- IONS 63.20
- Support Level
- SAIA $283.03
- IONS $41.28
- Resistance Level
- SAIA $313.52
- IONS $43.64
- Average True Range (ATR)
- SAIA 10.28
- IONS 1.36
- MACD
- SAIA 1.71
- IONS -0.06
- Stochastic Oscillator
- SAIA 49.12
- IONS 63.77
About SAIA Saia Inc.
Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.